Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GBIO 
Generation Bio Co (GBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 3 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.85% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.14M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 7 | Beta 2.66 | 52 Weeks Range 0.30 - 3.65 | Updated Date 06/30/2025 |
52 Weeks Range 0.30 - 3.65 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -292.92% | Operating Margin (TTM) -177.32% |
Management Effectiveness
Return on Assets (TTM) -18.97% | Return on Equity (TTM) -70.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -47518493 | Price to Sales(TTM) 0.82 |
Enterprise Value -47518493 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 5.1 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 67035200 | Shares Floating 49177049 |
Shares Outstanding 67035200 | Shares Floating 49177049 | ||
Percent Insiders 14.37 | Percent Institutions 72.37 |
Analyst Ratings
Rating 3 | Target Price 6.5 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Generation Bio Co
Company Overview
History and Background
Generation Bio Co. was founded in 2016 and is focused on developing genetic medicines for inherited liver diseases and other areas. Their focus is on non-viral gene therapy.
Core Business Areas
- Genetic Medicines: Developing and delivering durable genetic therapies by targeting specific disease pathways.
- Liver Diseases: Primarily focused on inherited liver diseases due to the liver's natural tropism.
- Immune Modulation: Developing genetic therapies to modulate the immune system for various diseases.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure is based on functional departments such as research, development, and operations.
Top Products and Market Share
Key Offerings
- AAV-Based Therapies (Preclinical): Gene therapy candidates using adeno-associated virus (AAV) vectors for treating liver diseases. No current market share. Competitors include companies developing gene therapies for liver diseases, such as Roche (RHHBY) and BioMarin Pharmaceutical Inc. (BMRN).
- Non-viral Platform: Developing a novel non-viral platform to deliver genetic medicines, aiming for improved safety and efficacy compared to traditional viral vectors. Competitors include companies focusing on non-viral gene delivery technologies.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increased regulatory approvals. It's highly competitive with many companies developing therapies for various genetic diseases.
Positioning
Generation Bio is positioned as an innovative player in the gene therapy space, leveraging a non-viral delivery platform to address challenges associated with viral vectors.
Total Addressable Market (TAM)
The gene therapy TAM is expected to reach billions of dollars in the coming years. Generation Bio's positioning within this TAM depends on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Innovative non-viral gene delivery platform
- Focus on inherited liver diseases with high unmet need
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- Limited clinical data
- High cash burn rate
Opportunities
- Potential to address limitations of viral gene therapies
- Expanding pipeline to other therapeutic areas
- Partnerships and collaborations with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established gene therapy companies
Competitors and Market Share
Key Competitors
- BMRN
- CRSP
- EDIT
- BLUE
Competitive Landscape
Generation Bio aims to differentiate itself with a non-viral delivery platform, addressing concerns about viral vector immunogenicity. Other established companies have head starts in particular therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on investment in research and development, which has been significant.
Future Projections: Future projections depend on the success of clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing their lead programs through clinical trials and expanding their platform technology.
Summary
Generation Bio is a high-risk, high-reward biotechnology company with an innovative non-viral gene delivery platform. Its success hinges on clinical trial outcomes and its ability to secure partnerships. The company faces significant competition and regulatory hurdles, making its future uncertain.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Generation Bio Co
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-06-12 | President, CEO & Director Dr. Cameron Geoffrey McDonough M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 115 | Website https://generationbio.com |
Full time employees 115 | Website https://generationbio.com | ||
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.